A poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Neurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
With great anticipation, the updated report of the TFOS Dry Eye WorkShop (DEWS II) was released last week. The first DEWS report was released in 2007.
So much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Scott Schachter, OD, discusses dry eye and how incorporating a dry eye checklist may help improve patient treatment.
Optometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.
ODs undervalue ocular point-of-care tear testing
Improve your scleral fitting skills and your patients’ quality of life
The British Contact Lens Association (BCLA) celebrated its 40th birthday June 9-11 at its 2017 clinical conference and exhibition in Liverpool, UK. Optometry Times was there to hear the latest and live tweet from the meeting.
At every age we need adequate, uninterrupted sleep for optimal, wakeful functioning. Insufficient sleep is associated with a number of chronic diseases and conditions such as diabetes, cardiovascular disease, obesity, and depression.